MiNK Therapeutics, Inc.

NasdaqCM INKT

MiNK Therapeutics, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024

MiNK Therapeutics, Inc. Cash and Short-Term Investments is NA for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: INKT

MiNK Therapeutics, Inc.

CEO	Dr. Jennifer S. Buell Ph.D.
IPO Date	Oct. 15, 2021
Location	United States
Headquarters	149 Fifth Avenue
Employees	31
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Key trends

Past 5 years